期刊
SEMINARS IN IMMUNOLOGY
卷 23, 期 1, 页码 42-49出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2011.01.003
关键词
Dendritic cells; T-cells; Innate immunity; Adaptive immunity; Anticancer immunity; Immunomodulation
类别
资金
- Ligue Nationale contre le Cancer
- Fondation pour la Recherche Medicale
- Association For International Cancer Research
- Canceropole Ile-de-France
- Institut National du Cancer
- Agence Nationale pour la Recherche
Dendritic cells (DCs) are central to the initiation of tumor-specific immune responses. However, the tumor microenvironment generates immunosuppressive cells and soluble mediators that compromise DC functions and limit the success of DC-based therapies. Progress in understanding DC metabolism in cancer is uncovering novel therapeutic targets that could restore DC capacity to prime T cells and trigger effective anticancer responses. Accumulating evidence also indicates that conventional chemo- and radiotherapy protocols can cause DC activation, enhance antigen cross-presentation, selectively eliminate immunosuppressive cells and revert the immunosuppression state caused by cancer, suggesting that relevant chemoimmunotherapy associations could fully exploit DC capacity to trigger anticancer responses. Here, we discuss recent strategies that harness DC against cancer. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据